RxDoctor Payments Data

Taylor Stone

Family · Calhoun, GANPI 1508441668

Payments from drug & device makers

$2,200in general payments, 2019–2025

Across 107 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$778
  • Sanofi$188
  • EMD Serono, Inc.$152
  • Regeneron Healthcare Solutions, Inc.$147
  • Novo Nordisk$138
  • Exact Sciences$129
  • plus $668 from 19 others

What the payments were for

  • Travel & lodging$603%
  • Food & beverage$2,09795%
  • Education$432%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,200 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$25,360
Medicare patients
133
Services billed
678

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide28$26,061
MounjaroTirzepatide13$16,201
FarxigaDapagliflozin Propanediol19$12,046
EliquisApixaban12$9,754
JanuviaSitagliptin Phosphate11$9,260
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$8,889
Dabigatran EtexilateDabigatran Etexilate Mesylate11$2,716
Albuterol Sulfate HfaAlbuterol Sulfate22$737
Omeprazole50$565
Rosuvastatin Calcium55$557
Levothyroxine Sodium56$426
Pantoprazole Sodium36$412
Famotidine20$327
Fluticasone Propionate30$325
Atorvastatin Calcium50$273

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$106$42,26341 claims
AstraZenecaFarxiga$64$12,04619 claims
PfizerEliquis$20$9,75412 claims
GSKTrelegy Ellipta$37$8,88915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Calhoun

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →